Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities

被引：36

作者：

Story-Roller, Elizabeth ^{[1
]}

Maggioncalda, Emily C. ^{[1
]}

Cohen, Keira A. ^{[2
]}

Lamichhane, Gyanu ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA

来源：

FRONTIERS IN MICROBIOLOGY | 2018年 / 9卷

关键词：

Mycobacterium abscessus; beta-lactams; peptidoglycan; LD-transpeptidase; beta-lactamase inhibitor; RAPIDLY GROWING MYCOBACTERIA; VITRO ANTIMICROBIAL SUSCEPTIBILITY; NONTUBERCULOUS MYCOBACTERIA; ANTIBIOTIC SUSCEPTIBILITY; SUBSP ABSCESSUS; CYSTIC-FIBROSIS; TUBERCULOSIS L; D-TRANSPEPTIDASE; NONCLASSICAL TRANSPEPTIDASE; CLINICAL-FEATURES; CRYSTAL-STRUCTURE;

D O I：

10.3389/fmicb.2018.02273

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

beta-lactams, the most widely used class of antibiotics, are well-tolerated, and their molecular mechanisms of action against many bacteria are well-documented. Mycobacterium abscessus (Mab) is a highly drug-resistant rapidly-growing nontuberculous mycobacteria (NTM). Only in recent years have we started to gain insight into the unique relationship between beta-lactams and their targets in Mab. In this mini-review, we summarize recent findings that have begun to unravel the molecular basis for overall efficacy of beta-lactams against Mab and discuss emerging evidence that indicates that we have yet to harness the full potential of this antibiotic class to treat Mab infections.

引用

页数：10

共 50 条

[1] Durlobactam in combination with β-lactams to combat Mycobacterium abscessus
Shin, Eunjeong
Dousa, Khalid M.
Taracila, Magdalena A.
Bethel, Christopher R.
Nantongo, Mary
Nguyen, David C.
Akusobi, Chidiebere
Kurz, Sebastian G.
Plummer, Mark S.
Daley, Charles L.
Holland, Steven M.
Rubin, Eric J.
Bulitta, Jurgen B.
Boom, W. Henry
Kreiswirth, Barry N.
Bonomo, Robert A.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (02)
[2] Mycobacterium abscessus: an emerging rapid-growing potential pathogen
Petrini, Bjorn
APMIS, 2006, 114 (05) : 319 - 328
[3] Mycobacterium abscessus: An emerging pulmonary pathogen
Roux, A. -L.
Herrmann, J. -L.
Gaillard, J. -L.
Rottman, M.
IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2010, 25 (01): : 26 - 33
[4] Bedaquiline Eliminates Bactericidal Activity of β-Lactams against Mycobacterium abscessus
Lindman, Marissa
Dick, Thomas
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
[5] A Case Report on Mycobacterium abscessus: An Emerging Pathogen
Chohan, Asad
Choudhury, Saiara
Taweesedt, Pahnwat T.
Dadhwal, Rahul
Vakil, Abhay P.
Ali, Zuhair
Franco, Rene
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
[6] In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus
Sanchez, Lea
Bitar, Maria
Herail, Quentin
Dorchene, Delphine
Hugonnet, Jean-Emmanuel
Arthur, Michel
Mainardi, Jean-Luc
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 1914 - 1918
[7] Mycobacterium abscessus: insights from a bioinformatic perspective
Sur, Saubashya
Patra, Tanushree
Karmakar, Mistu
Banerjee, Anindita
CRITICAL REVIEWS IN MICROBIOLOGY, 2023, 49 (04) : 499 - 514
[8] Human and mouse angiogenins: Emerging insights and potential opportunities
Sultana, Mst. Farzana
Abo, Hirohito
Kawashima, Hiroto
FRONTIERS IN MICROBIOLOGY, 2022, 13
[9] The Emerging Infections Network: Treatment Of Mycobacterium Abscessus And The Use Of Clofazimine
Novosad, S. A.
Winthrop, K. L.
Polgreen, P. M.
Beekmann, S. E.
Leitz, A.
Vu, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
[10] Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen
Victoria, Laura
Gupta, Amolika
Gomez, Jose Luis
Robledo, Jaime
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11

← 1 2 3 4 5 →